Group Total PFS (month) χ2 P value Average PFS Median PFS Treatment group 20 9.0 ± 0.7 9.1 ± 1.5 4.01 0.002 Control group 20 6.5 ± 0.4 7.2 ± 0.4

Table 2: The PFS of lung cancer patients in the two groups: The PFS of transfusion of cytokine-induced killer cells combined with chemotherapy and XIAOJI decoction hadsignificantly longer PFS than those treated with chemotherapy plus XIAOJI decoction with no CIK cell therapy (9.1 months vs. 7.2 months, P=0.002).